Conference Call and Webcast Scheduled for Tuesday, October 28 , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on October 28, 2025. The schedule for the press release and conference call / webcast is as follows: The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webca ...

INGREZZA was generally well tolerated over the long term, and TEAEs observed in the study were consistent with its established safety profile and with known symptoms of Huntington's disease:Â Additional presentations at the 2025 MDS International Congress of Parkinson's Disease and Movement Disorders include: , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT-HD2 study demonstrating an established long-term safety profile, tolerability and susta ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P 1500 Health Care Index declined 6.9% in the second quarter, underperforming the S&P 500’s 10.9% return. Health care providers & services, life science ...

The KINECT-PROâ"¢ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported. ...

SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRIâ"¢ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-1065845). ...

Question-and-Answer SessionGuys, first, I thought we'd start with maybe a brief overview of Neurocrine's strategy for developing and commercializing drugs for neuropsychiatric conditions. In particular, maybe which indications is Neurocrine most interested in? And what types of targets will Neurocrine prioritize?Kyle GanoCEO & Director Thanks, Phil. I'll take that question, and thanks for having us here this morning. Always a pleasure to get together. Your question is actually timely, it's timely for a coup ...

Neurocrine Biosciences (NasdaqGS:NBIX) FY Conference September 17, 2025 12:40 PM ET Company ParticipantsKyle Gano - CEOTodd Tushla - VP of Investor RelationsSanjay Keswani - Chief Medical OfficerConference Call ParticipantsPhil Nadeau - Managing Director and Senior Research AnalystPhil NadeauGood afternoon and welcome to TD Cowen's Neuroscience Summit. I'm Phil Nadeau, one of the biotech analysts here at TD Cowen, and it's my pleasure to moderate a fireside chat with Neurocrine Biosciences. We have with us ...

Additional Data from SAVITRIâ"¢ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO , Sept. 16, 2025 /PRNewswire/ --Â Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych Congress 2025, taking place September 17-21 in San Diego. ...

分析师观点与评级 - RBC Capital于9月5日将公司目标价从144美元上调至149美元 并维持“跑赢大盘”评级 [1] - 摩根斯坦利的Sean Laaman同日给予公司“买入”评级 目标价为163美元 [3] - 分析师共识评级为“强力买入” 目标价中位数为141.87美元 意味着较当前水平有19.83%的上涨空间 [3] 公司业务与产品 - 公司是一家专注于神经科学的生物制药公司 致力于研究、开发、销售和商业化治疗神经内分泌、神经和神经精神疾病的药物 [4] - 产品组合包括治疗亨廷顿病相关舞蹈症、迟发性运动障碍、经典先天性肾上腺皮质增生症(CAH)以及子宫内膜异位症和子宫肌瘤的药物 [4] 产品表现与市场预期 - 根据RBC Capital对处方趋势的最新分析 药物Crenessity的强劲上市势头预计将持续 其第三季度业绩有望超过市场共识预期 [2] - 公司股价已更接近公允价值 这可能表明近期乐观情绪正在增强 [2]

PresentationSean LaamanHead of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech equity research here at the firm. Before we commence, for important disclosures, go to our research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Neurocrine Biosciences, with ...